IGM Total Current Liabilities from 2010 to 2024
| IGMS Stock | USD 9.40 0.51 5.74% |
Total Current Liabilities | First Reported 2018-03-31 | Previous Quarter 37.7 M | Current Value 44 M | Quarterly Volatility 15.8 M |
Check IGM Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IGM Biosciences' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 8.7 M or Interest Expense of 8.3 M, as well as many indicators such as Price To Sales Ratio of 194, Dividend Yield of 0.0 or PTB Ratio of 2.25. IGM financial statements analysis is a perfect complement when working with IGM Biosciences Valuation or Volatility modules.
IGM | Total Current Liabilities |
Latest IGM Biosciences' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of IGM Biosciences over the last few years. Total Current Liabilities is an item on IGM Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of IGM Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. IGM Biosciences' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in IGM Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
IGM Total Current Liabilities Regression Statistics
| Arithmetic Mean | 12,098,407 | |
| Geometric Mean | 4,071,525 | |
| Coefficient Of Variation | 128.86 | |
| Mean Deviation | 12,721,476 | |
| Median | 976,000 | |
| Standard Deviation | 15,590,011 | |
| Sample Variance | 243T | |
| Range | 43.7M | |
| R-Value | 0.83 | |
| Mean Square Error | 83.1T | |
| R-Squared | 0.68 | |
| Significance | 0.0001 | |
| Slope | 2,880,295 | |
| Total Sum of Squares | 3402.7T |
IGM Total Current Liabilities History
About IGM Biosciences Financial Statements
IGM Biosciences shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although IGM Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in IGM Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on IGM Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 42.5 M | 23.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.